18,555 AbbVie Inc. $ABBV Shares Bought by Sanders Morris Harris LLC

Sanders Morris Harris LLC raised its position in AbbVie Inc. (NYSE:ABBV) by 972.5% during the third quarter, Holdings Channel reports. The institutional investor owned 20,463 shares of the company’s stock after buying an additional 18,555 shares during the quarter. Sanders Morris Harris LLC’s holdings in AbbVie were worth $5,358,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Consilium Wealth Advisory LLC raised its holdings in AbbVie by 6.7% during the 3rd quarter. Consilium Wealth Advisory LLC now owns 6,560 shares of the company’s stock worth $1,716,000 after buying an additional 411 shares during the period. N10 Wealth LLC acquired a new position in AbbVie during the 3rd quarter worth approximately $283,000. ABLE Financial Group LLC grew its stake in shares of AbbVie by 12.1% during the 3rd quarter. ABLE Financial Group LLC now owns 2,793 shares of the company’s stock worth $731,000 after acquiring an additional 301 shares in the last quarter. MinichMacGregor Wealth Management LLC boosted its holdings in AbbVie by 72.8% during the third quarter. MinichMacGregor Wealth Management LLC now owns 2,516 shares of the company’s stock worth $658,000 after purchasing an additional 1,060 shares during the last quarter. Finally, First Citizens Bank & Trust Co. grew its holdings in shares of AbbVie by 25.4% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 54,546 shares of the company’s stock valued at $14,269,000 after acquiring an additional 11,032 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Price Performance

AbbVie stock traded up $9.22 during mid-day trading on Wednesday, hitting $283.58. 5,620,782 shares of the company’s stock traded hands, compared to its average volume of 6,410,426. The firm has a 50 day simple moving average of $260.41 and a two-hundred day simple moving average of $237.87. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $285.40. The stock has a market cap of $501.03 billion, a price-to-earnings ratio of 80.11, a P/E/G ratio of 1.28 and a beta of 0.24.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts anticipate that AbbVie Inc. will post 13.95 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie’s payout ratio is 195.48%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Rothschild & Co Redburn lifted their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. BNP Paribas Exane increased their price target on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Leerink Partners raised their price target on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Sanford C. Bernstein restated a “market perform” rating and issued a $225.00 price target (up from $203.00) on shares of AbbVie in a research note on Tuesday, June 23rd. Finally, Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $277.18.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 AFFIRM data showed that subcutaneous SKYRIZI improved clinical and endoscopic outcomes versus placebo in adults with moderately to severely active Crohn’s disease, with safety consistent with its established profile. The results could support regulatory review of a more convenient induction option and strengthen AbbVie’s post-Humira immunology growth story. Did SKYRIZI’s Subcutaneous Crohn’s Data Just Shift AbbVie’s Immunology Investment Narrative?
• Positive Sentiment: Analysts remain constructive ahead of earnings. RBC reaffirmed an “outperform” rating and cited potential third-quarter top-line strength from RINVOQ, SKYRIZI and Vraylar, while Erste Group raised its 2027 EPS forecast to $16.34 from $16.19 and maintained a Buy rating. AbbVie Poised for Q3 Top-Line Beat
• Positive Sentiment: AbbVie benefited from a wider healthcare-sector rally, while unusually heavy call-option activity—86,296 calls purchased versus typical volume of 15,836—suggested increased short-term bullish positioning.
• Neutral Sentiment: Some investors and analysts are comparing AbbVie unfavorably with Sanofi, whose upgraded 2026 outlook, Dupixent growth and lower valuation may offer a more attractive risk-reward profile. This is a relative-investment consideration rather than a direct change to AbbVie’s fundamentals. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
• Negative Sentiment: RBC’s $280 price target is below the recently quoted trading level, indicating limited near-term upside at that target. A recent executive stock sale may also weigh modestly on sentiment, although it does not alter the company’s operating outlook.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.